RVU120 (XPO1 inhibitor)

About Ryvu Therapeutics

Ryvu Therapeutics is a Polish clinical-stage biotech focused on discovering and developing targeted small molecule therapies for cancer. Its strategy centers on tackling difficult-to-drug targets through a proprietary, integrated R&D platform, yielding a pipeline with both wholly-owned and partnered assets. Key achievements include advancing its lead program RVU120 into Phase I/II trials for hematological malignancies and securing a strategic partnership with BioNTech for its HPK1 inhibitor. The company aims to become a leader in precision oncology by translating novel biological insights into differentiated therapeutics.

Therapeutic Areas